Psoriatic Arthritis

Leveraging data from the 2020 UPLIFT survey, investigators offer an overview of the quality of life and treatment satisfaction among people with psoriasis and psoriatic arthritis in the US.

At the 2-year mark after methotrexate initiation, 71% of patients with psoriatic arthritis and 76% of patients with rheumatoid arthritis remained on methotrexate.

Sustained low disease activity/remission was associated with functional and health-related quality of life improvements.

Dr David Hudesman, Dr Jordan Axelrad, and Dr Jose Scher discuss strategies for managing coexisting inflammatory bowel disease and psoriatic arthritis and highlight the importance of a multidisciplinary approach to providing comprehensive care.

According to the study, these findings can inform policy decisions and assist in developing interventions aimed at reducing absenteeism and promoting the productivity of individuals with idiopathic inflammatory rheumatic diseases.

CCR East 2023 data show ixekizumab bettered adalimumab on measures of joint pain and quality of life in patients with PsA and concomitant nail plus DIP involvement.

Post-hoc analysis from DISCOVER-2 show patients who achieve a clinical response by week 8 generally go on to see quality-of-life improvements past 1 year.

An analysis of 11 late-stage clinical trials shows guselkumab provides a consistent and comparable safety profile to placebo in treated patients.

New data from CCR East show Black and Hispanic patients with PsA are significantly more likely to report worse health-related quality of life than White patients.

Patients with psoriatic arthritis and/or psoriasis reported improved BMI and HbA1C after 6 months of apremilast—with pronounced benefit among patients with obesity.

Data from the UPLIFT study show patients with psoriatic arthritis and their physicians see eye-to-eye on most subjects—except for treatment goals.

While age and fat mass were inversely associated with cardiorespiratory fitness (CRF), the physical activity index was positively associated with CRF.

An analysis of data from patients presented to a pair of clinics in Greece over a 5-year period provides insight into potential differences in disease course, management, and presentation of psoriatic arthritis based on age at diagnosis.

Results from the SELECT-PsA trials indicate patients with active PsA and axial involvement demonstrated greater clinical improvement with upadacitinib 15 mg versus placebo.

No significant changes in the rate of flares during the 6-month period pre- or post-vaccination were observed in patients with either rheumatoid arthritis or psoriatic arthritis.

Both drugs were well tolerated and without any serious adverse events.

Patients with psoriatic arthritis had increased risks of non-melanoma skin cancer, lymphoma, and thyroid cancer compared with the general population.

At month 3, patients treated with tofacitinib achieved higher rates of ACR20/50, MDA, and PASI75 in both sexes when compared with the placebo. However, female patients were less likely to achieve MDA when compared with males.

Soumya Chakravarty, MD, PhD, discussed the results of the DISCOVER-1 and DISCOVER-2 studies that evaluated the long-term efficacy of guselkumab for the treatment of adult patients with active psoriatic arthritis.

Treatment with secukinumab was safe and effective for patients with ankylosing spondylitis and psoriatic arthritis, with significant reductions in disease activity scores observed through 52 weeks.

The systematic review summarized the impact of biologics targeting the IL-23/Th17 axis.

The phase 3 DISCOVER-1 and DISCOVER-2 studies were used to evaluate dactylitis resolution in guselkumab-treated patients with psoriatic arthritis through 1 year.

Polypharmacy, defined as ≥5 concomitant drugs, was significantly higher in patients with psoriatic arthritis when compared with controls (49% vs 17%, respectively).

Results demonstrate that guselkumab was well-tolerated in studies continuing for 1 to 2 years among patients with active psoriatic arthritis regardless of TNFi experience.